SG Americas Securities LLC Purchases 72,341 Shares of Scholar Rock Holding Corporation $SRRK

SG Americas Securities LLC boosted its position in Scholar Rock Holding Corporation (NASDAQ:SRRK) by 602.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 84,349 shares of the company’s stock after purchasing an additional 72,341 shares during the period. SG Americas Securities LLC’s holdings in Scholar Rock were worth $3,716,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. AQR Capital Management LLC raised its stake in Scholar Rock by 609.3% in the first quarter. AQR Capital Management LLC now owns 57,294 shares of the company’s stock valued at $1,842,000 after buying an additional 49,217 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Scholar Rock by 12.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company’s stock valued at $1,709,000 after buying an additional 5,831 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Scholar Rock by 37.4% during the 1st quarter. Millennium Management LLC now owns 200,255 shares of the company’s stock worth $6,438,000 after acquiring an additional 54,555 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Scholar Rock by 25.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company’s stock worth $5,460,000 after acquiring an additional 34,594 shares during the last quarter. Finally, Strs Ohio acquired a new position in shares of Scholar Rock during the 1st quarter worth approximately $77,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

Scholar Rock Stock Performance

NASDAQ:SRRK opened at $50.01 on Friday. The stock has a 50 day simple moving average of $45.22 and a 200 day simple moving average of $40.75. The stock has a market cap of $5.75 billion, a P/E ratio of -14.58 and a beta of 0.68. Scholar Rock Holding Corporation has a 1-year low of $22.71 and a 1-year high of $50.50. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.41.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.10. During the same period last year, the business earned ($0.64) earnings per share. Research analysts anticipate that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current year.

Insider Buying and Selling at Scholar Rock

In related news, General Counsel Junlin Ho sold 9,580 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total value of $445,757.40. Following the transaction, the general counsel directly owned 241,545 shares in the company, valued at approximately $11,239,088.85. This represents a 3.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Mo Qatanani sold 8,484 shares of the firm’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $47.07, for a total transaction of $399,341.88. Following the transaction, the insider directly owned 98,445 shares in the company, valued at approximately $4,633,806.15. This represents a 7.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 207,464 shares of company stock worth $9,157,423. Insiders own 13.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on SRRK shares. Raymond James Financial restated a “strong-buy” rating on shares of Scholar Rock in a research note on Tuesday, March 3rd. Barclays upped their price objective on shares of Scholar Rock from $52.00 to $53.00 and gave the company an “overweight” rating in a report on Tuesday, March 3rd. Cantor Fitzgerald reissued an “overweight” rating on shares of Scholar Rock in a research report on Thursday, December 11th. Wedbush raised their target price on shares of Scholar Rock from $56.00 to $58.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, BMO Capital Markets lifted their target price on shares of Scholar Rock from $50.00 to $70.00 and gave the stock an “outperform” rating in a report on Wednesday, March 4th. Four research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Scholar Rock has an average rating of “Buy” and a consensus price target of $54.93.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).